Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $1.18 in the prior trading day, Protalix BioTherapeutics Inc. (AMEX: PLX) closed at $1.15, down -2.54%. In other words, the price has decreased by -$2.54 from its previous closing price. On the day, 0.96 million shares were traded. PLX stock price reached its highest trading level at $1.22 during the session, while it also had its lowest trading level at $1.09.
Ratios:
Our goal is to gain a better understanding of PLX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.12 and its Current Ratio is at 1.54. In the meantime, Its Debt-to-Equity ratio is 0.78 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 08, 2020, Reiterated its Buy rating but revised its target price to $11 from $3 previously.
On April 17, 2017, Rodman & Renshaw reiterated its Buy rating and also lowered its target price recommendation from $4 to $5.
On April 04, 2016, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $3.50.Rodman & Renshaw initiated its Buy rating on April 04, 2016, with a $3.50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 19 ’23 when Bashan Dror bought 64,516 shares for $1.40 per share. The transaction valued at 90,484 led to the insider holds 132,516 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PLX now has a Market Capitalization of 84009912 and an Enterprise Value of 65730944. As of this moment, Protalix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.22, and their Forward P/E ratio for the next fiscal year is 1.42. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.49. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.28 while its Price-to-Book (P/B) ratio in mrq is 2.50. Its current Enterprise Value per Revenue stands at 1.004 whereas that against EBITDA is 5.642.
Stock Price History:
Over the past 52 weeks, PLX has reached a high of $3.55, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -14.15%, while the 200-Day Moving Average is calculated to be -26.77%.
Shares Statistics:
The stock has traded on average 349.15K shares per day over the past 3-months and 384030 shares per day over the last 10 days, according to various share statistics. A total of 72.95M shares are outstanding, with a floating share count of 62.49M. Insiders hold about 14.46% of the company’s shares, while institutions hold 13.97% stake in the company. Shares short for PLX as of 1713139200 were 6703631 with a Short Ratio of 19.20, compared to 1710460800 on 6674487. Therefore, it implies a Short% of Shares Outstanding of 6703631 and a Short% of Float of 9.43.
